Radical hysterectomy for stage IIB cervical cancer: A review

International Journal of Gynecological Cancer

Volumn 15, Issue 6, 2005, Pages 995-1001

  Suprasert, Prapaporn ^a   Srisomboon, J ^a   Kasamatsu, T ^b  

^a Faculty of Medicine Chiang Mai University   (Thailand)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Cervical cancer; Radical hysterectomy; Stage IIB

Indexed keywords

CISPLATIN;

CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MEDICAL LITERATURE; MEDLINE; METASTASIS; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; UTERINE CERVIX CANCER;

COMBINED MODALITY THERAPY; FEMALE; HUMANS; HYSTERECTOMY; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 30944451529     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2005.00259.x     Document Type: Review

References (22)

1. Annual report from Cancer Registry Committee of Japan Society of Obstetrics and Gynecology. Acta Obstet Gynaecol Jpn 1983;35:737-52.
2. Matsuyama T, Inoue I, Tsukamoto N et al. Stage Ib, IIa, and IIb cervix cancer, postsurgical staging, and prognosis. Cancer 1984;54:3072-7.
3. Inoue T, Okumura M. Prognostic significance of parametrial extension in patients with cervical carcinoma stages IB, IIA, and IIB. A study of 628 cases treated by radical hysterectomy and lymphadenectomy with or without postoperative irradiation. Cancer 1984;54:1714-9.
4. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990;65:1923-7.
5. Burghardt E, Pickel H, Haas J, Lahousen M. Prognostic factors and operative treatment of stages IB to IIB cervical cancer. Am J Obstet Gynecol 1987;156:988-96.
6. Girardi F, Lichtenegger W, Tamussino K, Haas J. The importance of parametrial lymph nodes in the treatment of cervical cancer. Gynecol Oncol 1989;34:206-11.
7. Kamura T, Tsukamoto N, Tsuruchi N et al. Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection-an analysis with mathematical statistics. Int J Gynecol Cancer 1993;3:219-25.
8. Kawagoe T, Kashimura M, Matsuura Y, Sugihara K, Toki N, Aoki T. Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix. Int J Gynecol Cancer 1999;9:421-6.
9. Noguchi H, Shiozawa I, Sakai Y, Yamazaki T, Fukuta T. Pelvic lymph node metastasis of uterine cervical cancer. Gynecol Oncol 1987;27:150-8.
10. Okada M, Kigawa J, Minagawa Y et al. Indication and efficacy of radiation therapy following radical surgery in patients with stage IB to IIB cervical cancer. Gynecol Oncol 1998;70:61-4.
11. Sakuragi N, Satoh C, Takeda N et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 1999;85:1547-54.
12. Takeda N, Sakuragi N, Takeda M et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002;81:1144-51.
13. Winter R, Haas J, Reich O et al. Parametrial spread of cervical cancer in patients with negative pelvic lymph nodes. Gynecol Oncol 2002;84:252-7.
14. Benedetti-Panici P, Maneschi F, D'Andrea G et al. Early cervical carcinoma, the natural history of lymph node involvement redefined on the basis of thorough parametrectomy and giant section study. Cancer 2000; 88:2267-74.
15. Toita T, Mitsuhashi N, Teshima T et al. Japanese PCS Working Subgroup for Uterine Cervical Cancer. Post-operative radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan. Jpn J Clin Oncol 2004;34:99-103.
16. Peters WA III, Liu PY, Barrett RJ II et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13.
17. Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A et al. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol 2003;14: 1278-84.
18. Lahousen M, Haas J, Pickel H et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: a randomized, prospective, multicenter trial. Gynecol Oncol 1999;73: 196-201.
19. Trattner M, Graf AH, Lax S et al. Prognostic factors in surgically treated stage ib-iib cervical carcinomas with special emphasis on the importance of tumor volume. Gynecol Oncol 2001;82:11-6.
20. Aoki Y, Sasaki M, Watanabe M et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. Gynecol Oncol 2000;77: 305-9.
21. Comerci G, Bolger BS, Flannelly G, Maini M, de Barros Lopes A, Monaghan JM. Prognostic factors in surgically treated stage IB-IIB carcinoma of the cervix with negative lymph nodes. Int J Gynecol Cancer 1998;8:23-6.
22. Kjorstad KE, Martimbeau PW, Iversen T. Stage IB carcinoma of the cervix, the Norwegian Radium Hospital: results and complications. III. Urinary and gastrointestinal complications. Gynecol Oncol 1983;15:42-7.